Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal changes in the macular, resulting in reduced vision and distorted objects.
Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy – Pharmaceutical Technology
Share this article The FDA placed a clinical hold on the trial for HEMO-CAR-T in June, requesting additional information from Hemogenyx. Credit: JHVEPhoto via Shutterstock.